Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ)
CNY 17.07
(1.01%)
CNY 17.07
(1.01%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 63.03 Million CNY | 39.83% |
| 2022 | 45.07 Million CNY | 29.77% |
| 2021 | 34.73 Million CNY | 81.31% |
| 2020 | 19.15 Million CNY | -28.84% |
| 2019 | 26.92 Million CNY | -66.85% |
| 2018 | 81.22 Million CNY | -9.76% |
| 2017 | 90.01 Million CNY | -1.55% |
| 2016 | 91.42 Million CNY | -8.57% |
| 2015 | 100 Million CNY | -9.09% |
| 2014 | 110 Million CNY | -20.29% |
| 2013 | 138 Million CNY | 1616.59% |
| 2012 | 8.03 Million CNY | 0.0% |
| 2011 | - CNY | -100.0% |
| 2010 | 20 Million CNY | -88.89% |
| 2009 | 180 Million CNY | 8.52% |
| 2008 | 165.87 Million CNY | -20.65% |
| 2007 | 209.03 Million CNY | 38.2% |
| 2006 | 151.25 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 84.78 Million CNY | -1.26% |
| 2024 Q1 | 71.88 Million CNY | 14.04% |
| 2024 Q2 | 90.77 Million CNY | 26.28% |
| 2023 Q3 | 51.26 Million CNY | -14.89% |
| 2023 Q1 | 65.7 Million CNY | 45.74% |
| 2023 FY | 63.03 Million CNY | 39.83% |
| 2023 Q4 | 63.03 Million CNY | 22.97% |
| 2023 Q2 | 60.23 Million CNY | -8.32% |
| 2022 Q3 | 46.6 Million CNY | -7.29% |
| 2022 FY | 45.07 Million CNY | 29.77% |
| 2022 Q4 | 45.07 Million CNY | -3.28% |
| 2022 Q1 | 41.96 Million CNY | 20.8% |
| 2022 Q2 | 50.27 Million CNY | 19.79% |
| 2021 Q1 | 25.15 Million CNY | 31.28% |
| 2021 Q3 | 6.68 Million CNY | -62.41% |
| 2021 FY | 34.73 Million CNY | 81.31% |
| 2021 Q4 | 34.73 Million CNY | 419.85% |
| 2021 Q2 | 17.77 Million CNY | -29.32% |
| 2020 Q1 | 20 Million CNY | -25.72% |
| 2020 Q2 | - CNY | -100.0% |
| 2020 FY | 19.15 Million CNY | -28.84% |
| 2020 Q3 | - CNY | 0.0% |
| 2020 Q4 | 19.15 Million CNY | 0.0% |
| 2019 Q2 | 57.77 Million CNY | 92.59% |
| 2019 Q3 | 28.2 Million CNY | -51.18% |
| 2019 FY | 26.92 Million CNY | -66.85% |
| 2019 Q1 | 30 Million CNY | -63.07% |
| 2019 Q4 | 26.92 Million CNY | -4.55% |
| 2018 Q4 | 81.22 Million CNY | 80.5% |
| 2018 FY | 81.22 Million CNY | -9.76% |
| 2018 Q3 | 45 Million CNY | -25.0% |
| 2018 Q2 | 60 Million CNY | -7.69% |
| 2018 Q1 | 65 Million CNY | -27.79% |
| 2017 FY | 90.01 Million CNY | -1.55% |
| 2017 Q4 | 90.01 Million CNY | 20.01% |
| 2017 Q3 | 75 Million CNY | 10.29% |
| 2017 Q2 | 68 Million CNY | -2.86% |
| 2017 Q1 | 70 Million CNY | -23.44% |
| 2016 Q1 | 90 Million CNY | -10.0% |
| 2016 Q2 | 80 Million CNY | -11.11% |
| 2016 Q4 | 91.42 Million CNY | 14.29% |
| 2016 Q3 | 80 Million CNY | 0.0% |
| 2016 FY | 91.42 Million CNY | -8.57% |
| 2015 Q4 | 100 Million CNY | -16.67% |
| 2015 FY | 100 Million CNY | -9.09% |
| 2015 Q3 | 120 Million CNY | -7.69% |
| 2015 Q2 | 130 Million CNY | 30.0% |
| 2015 Q1 | 100 Million CNY | -9.09% |
| 2014 Q1 | 135 Million CNY | -2.17% |
| 2014 FY | 110 Million CNY | -20.29% |
| 2014 Q4 | 110 Million CNY | 22.22% |
| 2014 Q3 | 90 Million CNY | -33.33% |
| 2014 Q2 | 135 Million CNY | 0.0% |
| 2013 Q1 | - CNY | -100.0% |
| 2013 FY | 138 Million CNY | 1616.59% |
| 2013 Q2 | 28.5 Million CNY | 0.0% |
| 2013 Q3 | 118.5 Million CNY | 315.79% |
| 2013 Q4 | 138 Million CNY | 16.46% |
| 2012 Q4 | 8.03 Million CNY | 0.0% |
| 2012 Q1 | - CNY | 0.0% |
| 2012 FY | 8.03 Million CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q1 | - CNY | -100.0% |
| 2011 FY | - CNY | -100.0% |
| 2011 Q3 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 Q2 | 20 Million CNY | -81.82% |
| 2010 Q4 | 20 Million CNY | 0.0% |
| 2010 FY | 20 Million CNY | -88.89% |
| 2010 Q1 | 110 Million CNY | -38.89% |
| 2010 Q3 | 20 Million CNY | 0.0% |
| 2009 Q4 | 180 Million CNY | 0.0% |
| 2009 FY | 180 Million CNY | 8.52% |
| 2009 Q2 | 266.19 Million CNY | 0.0% |
| 2008 FY | 165.87 Million CNY | -20.65% |
| 2007 FY | 209.03 Million CNY | 38.2% |
| 2006 FY | 151.25 Million CNY | 0.0% |